Abstract
This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 expression by the glioblastoma key driver mutations. The expression of the CXCR4 receptor, and of its ligand stromal derived factor 1 (SDF-1, CXCL12), is maintained by intracellular pathways via positive feedback loops, and is associated with the epithelial mesenchymal transition (EMT) and the generation and self-renewal of cancer stem cells. SDF-1 and CXCR4 also play a role in the generation and maintenance of the perivascular stem cell niche which contains these cancer stem cells. The available data suggest that most, if not all, glioblastoma cancer stem cells rely on CXCR4 mediated signalling to maintain their phenotype. SDF-1 and CXCR4 are alsoinvolved in many other aspects of brain tumour biology including resistance to radio- and chemotherapy, the migration of cancer cells through the brain, the generation of the tumour blood supply and the recruitment of vascular progenitor cells. These properties suggest that a CXCR4 antagonist would help in the control of this disease.
Keywords: Cancer stem cell, CXCL12, CXCR4, EMT, glioblastoma, SDF-1, signaling.
Anti-Cancer Agents in Medicinal Chemistry
Title:CXCR4 and Glioblastoma
Volume: 16 Issue: 1
Author(s): Peter J. Richardson
Affiliation:
Keywords: Cancer stem cell, CXCL12, CXCR4, EMT, glioblastoma, SDF-1, signaling.
Abstract: This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 expression by the glioblastoma key driver mutations. The expression of the CXCR4 receptor, and of its ligand stromal derived factor 1 (SDF-1, CXCL12), is maintained by intracellular pathways via positive feedback loops, and is associated with the epithelial mesenchymal transition (EMT) and the generation and self-renewal of cancer stem cells. SDF-1 and CXCR4 also play a role in the generation and maintenance of the perivascular stem cell niche which contains these cancer stem cells. The available data suggest that most, if not all, glioblastoma cancer stem cells rely on CXCR4 mediated signalling to maintain their phenotype. SDF-1 and CXCR4 are alsoinvolved in many other aspects of brain tumour biology including resistance to radio- and chemotherapy, the migration of cancer cells through the brain, the generation of the tumour blood supply and the recruitment of vascular progenitor cells. These properties suggest that a CXCR4 antagonist would help in the control of this disease.
Export Options
About this article
Cite this article as:
Richardson J. Peter, CXCR4 and Glioblastoma, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (1) . https://dx.doi.org/10.2174/1871520615666150824153032
DOI https://dx.doi.org/10.2174/1871520615666150824153032 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Gene Expression Profiles in Breast Cancer to Identify Estrogen Receptor Target Genes
Mini-Reviews in Medicinal Chemistry Expression of Cytochrome P450 in Lung Tumor
Current Drug Metabolism Current Advances in Gene Therapy for the Treatment of Genodermatoses
Current Gene Therapy Differential Gene Expression in the Nucleus Accumbens and Frontal Cortex of Lewis and Fischer 344 Rats Relevant to Drug Addiction
Current Neuropharmacology A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design Metabolic Regulation by the Hexosamine Biosynthesis/O-Linked N-Acetyl Glucosamine Pathway
Current Signal Transduction Therapy Topical Ingenol Mebutate: A New Treatment Modality for Multiple Actinic Keratoses and Field Cancerization
Anti-Cancer Agents in Medicinal Chemistry Probiotics as a Tool to Biosynthesize Metallic Nanoparticles: Research Reports and Patents Survey
Recent Patents on Drug Delivery & Formulation Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Actinic Keratosis: Review of the Literature and New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design Current Drug Targets for Thymic Neoplasms
Current Cancer Drug Targets Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design K-Ras, Intestinal Homeostasis and Colon Cancer
Current Clinical Pharmacology PAX6 expression may be protective against dopaminergic cell loss in Parkinson’s disease
CNS & Neurological Disorders - Drug Targets